$ANNX

Annexon, Inc.

Annexon is a biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases of the body, brain and eye. Its platform focuses on blocking the classical complement pathway, and its research spans autoimmune disease, neurodegeneration and ophthalmology. Its product candidates include tanruprubart, an investigational infusion for Guillain-Barré Syndrome; vonaprument, an investigational intravitreal treatment for geographic atrophy; and ANX1502, an oral small molecule for autoimmune conditions. Other candidates include ANX009 for lupus nephritis. Annexon develops its product candidates and holds worldwide development and commercialization rights, including through exclusive licenses. It plans to pursue independent development and commercialization in indications and markets it can address with a focused sales and marketing organization, and to explore licensing agreements, collaborations or partnerships for other markets and indications. Annexon is headquartered in Brisbane, California.

No enriched coverage for $ANNX in the last 7 days.

No SEC Form 4 filings for $ANNX in the last 30 days.

See all $ANNX insider activity →
High

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

Annexon Biosciences GAAP EPS of -$0.25 (ANNX:NASDAQ)

Annexon Biosciences (ANNX) reported a Q3 GAAP EPS of -$0.25. The company has $213 million in cash and short-term investments, expected to last into 2028. Annexon also discussed its vonaprument Phase III ARCHER II trial and plans for a Q4 BLA filing for tanruprubart.

ANNX sentiment & insider activity

Recent ANNX coverage spans financial news, earnings and insider activity.

What's driving ANNX

AlphAI scores every news story that mentions ANNX with an AI model for sentiment and relevance, and aggregates insider trades from Annexon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ANNX

Score

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMedEarnings

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday - Microsoft (NASDAQ:MSFT)

Analysts updated price targets for several companies. Bernstein raised Microsoft's target to $662, maintaining an Outperform rating. Morgan Stanley increased Global-E Online's target to $50 and upgraded it to Overweight. Other notable changes include Truist Financial, Annexon, Ameriprise Financial, Lyft, A O Smith, Hudson Pacific Properties, Boyd Gaming, and Veradermics.

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

Related tickers